Gene expression and proteomic analysis to identify predictive biomarkers of response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2 positive or triple negat
Authors: Petricoin, E.F., Wulfkuhle, J., Hickish, T., El-Hariry, I., Reichert, V., Vukovic, V.M., Cameron, D.A., Awada, A. and Spector, N.
Journal: CANCER RESEARCH
Volume: 74
Issue: 19
eISSN: 1538-7445
ISSN: 0008-5472
DOI: 10.1158/1538-7445.AM2014-1612
Source: Web of Science (Lite)